Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma and AstraZeneca have announced the approval of the dry-power inhaler Symbicort Turbuhaler for the additional indication of chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
Symbicort Turbuhaler is a combination product containing a long-acting ß2 agonist with a bronchodilating action that is the mainstay of drug-based COPD therapy, and an inhaled corticosteroid, which reduces exacerbations of COPD.
The dry-power inhaler can reduce exacerbations of COPD and has a rapid onset of action, substantially contributing to an improved quality-of-life (QOL) for COPD patients.
The COPD patients are supposed to inhale Symbicort Turbuhaler four times per day with a daily dose is 640µg of budesonide and 18µg of formoterol fumarate hydrate.
The product was launched in January 2010 as a twice-daily, dry-power inhaler combination product for the treatment of bronchial asthma in Japan.